Company Filing History:
2 out of 1,744 
2 out of 5,089 
2 out of 34 
Years Active: 2023-2024
Title: **Philippe Bertolino: Pioneering Innovations in Pancreatic Cancer Diagnostics and Treatment**
Introduction
Philippe Bertolino is an accomplished inventor based in Lyons, France, recognized for his significant contributions to the medical field, particularly in the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC). With two patents to his name, Bertolino's work exemplifies the intersection of innovative research and practical medical applications.
Latest Patents
Bertolino's latest patents focus on a groundbreaking non-invasive method for assessing an individual's risk of developing pancreatic ductal adenocarcinoma. This method involves measuring the level of βig-h3 protein in blood samples, which has been found to positively correlate with PDAC risk. Rigorous studies conducted on two distinct patient cohorts, comprising 20 and 104 individuals, as well as a PDAC mouse model, demonstrated that βig-h3 can be detected early in the tumorigenesis process. The findings suggest that the presence of βig-h3 in the blood may serve as an early indicator of pancreatic neoplastic lesions. In addition to the diagnostic aspect, Bertolino's research also involves the use of βig-h3 antagonists for treating PDAC. These antagonists have shown promise in enhancing the anti-tumoral response of CD8T cells, thereby improving tumor growth outcomes when neutralizing βig-h3 antibodies are applied.
Career Highlights
Throughout his career, Philippe Bertolino has worked with prestigious research institutions that include the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Centre National de la Recherche Scientifique (CNRS). His affiliation with these organizations underlines his commitment to advancing medical science and his active role in pioneering significant innovations in the field of cancer research.
Collaborations
Bertolino has collaborated with notable peers in his field, including Kim In-San and Ana Hennino, contributing to the development and refinement of his innovative methods in cancer diagnostics and treatment. These collaborations highlight the importance of teamwork and collective expertise in achieving breakthroughs in medical research.
Conclusion
Philippe Bertolino's contributions to the field of pancreatic cancer diagnostics and treatment reflect his dedication to innovation and his role as a leading inventor. Through his pioneering patents, he continues to pave the way for non-invasive methods that could significantly improve early detection and treatment outcomes for pancreatic ductal adenocarcinoma. His work not only enhances our understanding of PDAC but also offers hope for more effective therapies in the future.